J&J’s Experimental Prostate Cancer Drug Shows Promise in Early-Stage Trial

Johnson & Johnson’s experimental prostate cancer drug JNJ-6143 has demonstrated promising anti-tumor activity in an early-stage clinical trial involving patients with advanced disease. The once-daily oral medicine is being developed for people whose cancer has progressed despite multiple previous treatments, a group that can have limited therapeutic options.

The findings, presented at the 2026 European Society for Medical Oncology (ESMO) Congress, suggest that the drug’s novel mechanism may offer another approach to treating difficult-to-treat prostate cancer. However, JNJ-6143 is still undergoing clinical evaluation. The results do not yet establish whether it improves survival, produces lasting responses or is safer or more effective than existing therapies.

Key Takeaways

• Drug: JNJ-6143, formerly known as HLD-0915, is an experimental oral prostate cancer treatment developed using Halda Therapeutics’ RIPTAC technology.
• PSA response: In the 50-milligram group, 77% of 31 evaluable patients experienced a PSA decline of at least 50%.
• Major PSA reductions: Nearly half of those patients, 48%, recorded a PSA decline of at least 90%.
• Tumor response: Imaging showed a confirmed complete or partial response in 69% of patients with measurable tumors.
• Safety: Reported side effects included nausea and elevated cholesterol and triglyceride levels.
• Development stage: The medicine remains investigational, and additional research is needed to establish its long-term benefits and risks.

What Did the Early-Stage Trial Find?

The trial evaluated JNJ-6143 in people with advanced prostate cancer who had already received multiple treatments. This is a clinically important group because cancer can become harder to control when it progresses despite earlier therapies.

Among 31 evaluable patients receiving the 50-milligram dose, the reported results showed substantial changes in PSA levels.

Trial measure	Reported result
Patients evaluated for PSA response at 50 mg	31
Patients with a PSA decline of at least 50%	77%
Patients with a PSA decline of at least 90%	48%
Confirmed complete or partial tumor response among patients with measurable tumors	69%

Source: Reuters.

The PSA results indicate that the drug had biological activity in a substantial proportion of patients in the evaluated dose group. Imaging results provide another measure of how tumors responded to treatment.

However, these percentages describe different outcomes and may involve different patient denominators. They should not be combined into a single success rate.

The study is also early-stage research. A small group of patients can provide important evidence about a drug’s potential, but it cannot establish how consistently the treatment will work across a broader population or whether responses will last.

Why PSA Levels Matter in Prostate Cancer

Prostate-specific antigen, or PSA, is a protein produced by cells in the prostate. Doctors commonly measure PSA levels in the blood to help assess prostate cancer and monitor how the disease responds to treatment.

A substantial decline in PSA can indicate that a treatment is affecting the cancer. In the JNJ-6143 study, the proportion of patients experiencing large declines was one of the encouraging signals.

Nevertheless, PSA is only one measure of treatment response. A lower PSA level does not automatically mean that all cancer has disappeared, that the disease has stopped progressing permanently or that a patient will live longer.

Researchers therefore assess PSA changes alongside imaging results, safety data, the duration of responses and other clinical outcomes. Longer follow-up will be needed to determine whether the early signals associated with JNJ-6143 translate into meaningful benefits for patients.

How JNJ-6143 Is Designed to Attack Cancer Cells

JNJ-6143 uses a technology known as Regulated Induced Proximity Targeting Chimera, or RIPTAC. The approach is designed to bring two proteins together inside cancer cells to disrupt processes the cells need to survive.

The medicine targets the androgen receptor, a protein expressed at high levels in many prostate cancer cells, and BRD4, a protein involved in regulating gene activity and supporting cellular functions.

The drug is designed to bind the androgen receptor and bring it into proximity with BRD4. This interaction is intended to interfere with BRD4’s normal activity in cells expressing the targeted androgen receptor, disrupting essential cellular processes and ultimately triggering cancer-cell death.

This mechanism differs from conventional prostate cancer treatments that primarily suppress androgen production or block androgen-receptor signalling. Those established approaches are important because prostate cancer often depends on androgen-related pathways to grow. However, some tumors eventually progress despite hormone-directed treatment.

JNJ-6143 is being investigated as a different way to exploit the biology of prostate cancer cells. Whether this strategy provides a clinically meaningful advantage over available treatments remains to be established through further trials.

What Side Effects Have Been Reported?

Early clinical development evaluates not only whether a drug affects a disease but also whether it can be administered safely.

Reported side effects associated with JNJ-6143 included nausea and elevated cholesterol and triglyceride levels. One patient discontinued treatment because of adverse effects, according to Reuters.

Cholesterol and triglycerides are blood fats that are routinely monitored because abnormal levels can affect cardiovascular health. Researchers will need to determine how frequently these changes occur, how severe they become and whether they can be managed while patients remain on treatment.

The available findings do not establish the complete safety profile of JNJ-6143. Larger studies and longer follow-up will be necessary to identify less common side effects and assess the balance between benefits and risks.

Patients should not stop, replace or change prescribed prostate cancer treatment based on early results from an investigational drug. Treatment decisions should be made with an oncology team familiar with the patient’s condition and available options.

J&J’s $3.05 Billion Acquisition Behind the Drug

Johnson & Johnson gained access to JNJ-6143 through its acquisition of Halda Therapeutics, a biotechnology company developing medicines based on the RIPTAC platform. The acquisition, valued at approximately $3.05 billion, was completed in December 2025.

The transaction expanded J&J’s oncology research portfolio with a technology designed to interfere with cancer-cell survival by bringing selected proteins together.

JNJ-6143, previously called HLD-0915, is the first investigational compound from the RIPTAC platform to advance into clinical studies. J&J says the medicine is being evaluated in Phase 1 and Phase 2 studies involving patients with metastatic prostate cancer.

The company’s presentation at ESMO 2026 marked an important public update on the program following the acquisition. The findings could help researchers determine the appropriate dose and design subsequent studies.

For J&J, the investment’s long-term value will depend on whether the experimental medicine demonstrates sufficiently strong efficacy and safety to advance through clinical development and eventually receive regulatory approval.

What Happens Next?

JNJ-6143 will require additional clinical testing to establish whether its early activity translates into lasting patient benefits. Researchers will need to evaluate how long PSA reductions and tumor responses persist, whether the drug delays disease progression and whether it improves survival or quality of life.

Further studies will also help determine which patients are most likely to benefit and how the medicine might fit alongside existing treatments. The current results do not establish that JNJ-6143 is superior to approved therapies or that it will work in every form of prostate cancer.

The drug’s future will depend on the strength and consistency of its evidence as trials progress. Although the early findings are promising, its role in prostate cancer care remains uncertain.

The Bigger Picture

The JNJ-6143 findings illustrate why pharmaceutical companies continue to investigate new mechanisms for treating cancers that become resistant to existing therapies. Rather than relying only on conventional hormone-blocking strategies, RIPTAC technology aims to disrupt essential cellular processes through a targeted interaction between proteins.

For patients with advanced prostate cancer, additional treatment approaches could eventually broaden the available options. But promising early results are the beginning of that process, not its conclusion. Larger studies must establish whether the approach delivers durable clinical benefits and an acceptable safety profile.

The research also demonstrates the potential value of biotechnology acquisitions in bringing experimental technologies into larger pharmaceutical development programs. J&J’s investment in Halda has produced an early clinical milestone, but the drug’s eventual medical and commercial impact will depend on the results of future trials.

FAQs

1. What is JNJ-6143?

JNJ-6143 is an experimental, once-daily oral medicine being developed by Johnson & Johnson for advanced prostate cancer. It was previously known as HLD-0915 and uses the RIPTAC technology platform.

2. How effective was the drug in the early trial?

Among 31 evaluable patients receiving the 50-milligram dose, 77% experienced a PSA decline of at least 50%, and 48% had a decline of at least 90%. Imaging showed a confirmed complete or partial response in 69% of patients with measurable tumors.

3. Is JNJ-6143 approved for prostate cancer treatment?

No. It remains an investigational medicine undergoing clinical evaluation. The early results do not mean it is approved for routine treatment.

4. How does JNJ-6143 work?

The drug uses RIPTAC technology to bring the androgen receptor and BRD4 proteins together. It is designed to disrupt BRD4’s activity in targeted cancer cells and interfere with processes required for cell survival.

5. What side effects have been reported?

Reported side effects include nausea and elevated cholesterol and triglyceride levels. Further clinical studies are needed to establish the medicine’s full safety profile.

Looking Ahead

The next important milestone for JNJ-6143 will be additional clinical evidence showing whether its early tumor responses can be sustained and whether the medicine improves meaningful outcomes for patients with advanced prostate cancer. Researchers will also need to establish an appropriate dose and better understand the risks associated with longer-term treatment.

For now, the findings offer an encouraging early signal for J&J’s RIPTAC research program, but they should be interpreted cautiously. The drug’s ultimate significance will depend on the results of larger studies and whether regulators conclude that its benefits outweigh its risks.